A novel gene therapy targeting Alzheimer’s disease will be evaluated in a Phase 1 clinical trial led by the University of California San Diego School…
Biogen and its Japanese partner Eisai announced Oct. 22nd an unexpected reversal—pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for…
AbbVie terminated a clinical trial of its intravenously administered antibody, designed to slow the progression of Progressive Supranuclear Palsy (PSP), as it failed to show…
The Alzheimer’s Association gave $6 million to the University of California, Davis, to fund its participation in the U.S. POINTER study, a landmark effort to…
After a review of the clinical data, sponsors Amgen and Novartis have concluded that the potential benefit for participants in a Alzheimer’s disease program did…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
